CytomX Therapeutics (CTMX) Tops Q2 EPS by 17c

CytomX Therapeutics (NASDAQ: CTMX) reported Q2 EPS of ($0.02), $0.17 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $24.7 million versus the consensus estimate of $13.68 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• B.Riley on Nayax (NYAX): 'Sell-Off Overshoots the Story'
• AutoZone (AZO) Tops Q4 EPS by $1.76, Misses on Revenue